{"id":44982,"date":"2012-05-17T12:20:47","date_gmt":"2012-05-17T12:20:47","guid":{"rendered":"http:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/uncategorized\/applied-genetics-signs-agreement-with-the-national-university-of-mexico-unam.php"},"modified":"2012-05-17T12:20:47","modified_gmt":"2012-05-17T12:20:47","slug":"applied-genetics-signs-agreement-with-the-national-university-of-mexico-unam","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/human-genetics\/applied-genetics-signs-agreement-with-the-national-university-of-mexico-unam.php","title":{"rendered":"Applied Genetics Signs Agreement With The National University Of Mexico (UNAM)"},"content":{"rendered":"<p><p>    WESTMINSTER, Colo., May 16, 2012 \/PRNewswire\/ -- GeneThera, Inc.    (GTHR.PK)    announced today that Applied Genetics, GeneThera's majority    owned subsidiary, signed a research and test validation    agreement with Universidad National Autonoma de    Mexico (UNAM). Scope of the agreement is to validate    GeneThera proprietary Johne's disease (JD) HerdCheck Field    Collection System (FCS) Molecular Assay in Mexico. Dr. Tony    Milici, interim president of Applied Genetics and CEO of    GeneThera, stated, \"This agreement is another major milestone    in establishing GeneThera and Applied Genetics' leadership in    the field of Johne's disease molecular testing. UNAM's support    is of fundamental importance to speed up the validation process    of GeneThera's Johne's disease molecular testing, which will    lead to JD test approval by the Mexican Government.\"  <\/p>\n<p>    Dr. Gilberto Chaves Griz, Professor of Veterinary Pathology, in    the Department of Veterinary medicine at UNAM and Director of    the Johne's Disease Center, who is one of the world's most    renowned expert in the field of Johne's disease declared, \"We    are very pleased to partner with Applied Genetics and GeneThera    to work on this project. It is extremely critical that we can    diagnose JD in Mexico using the most advanced technology    available. It is also of paramount importance to establish a    Johne's disease program at the national level. Mexico has one    of the largest cows, goat and sheep populations in Northern and    Central America, yet no data exists to the extent of Johne's    infection in these animals. It is our firm intention to    establish a National Testing Program for Johne's Disease in    Mexico with the help of Applied Genetics and GeneThera's state    of the art technology.\" UNAM is the largest University in    Mexico. Applied Genetics is a molecular diagnostic company that    focuses on commercializing molecular testing for Johne's    disease in Mexico.  <\/p>\n<p>    Johne's disease is a global devastating and incurable disease    of dairy cows, sheep and goats caused by a bacterium called    Mycobacterium Paratuberculosis sub. Avium, (MAP). Dairy    products, contaminated with MAP, are the vehicles by which the    infection spreads in the human intestine triggering the onset    of Crohn's disease. Applied Genetics employs the use of    GeneThera HerdCheck to test and control the spread of Johne's    disease in Mexico. HerdCheck is a proprietary molecular    diagnostic system based on the use of high throughput robotics    and Real time PCR.  <\/p>\n<p>    About GeneThera, Inc.  <\/p>\n<p>    GeneThera, Inc. is a molecular biotechnology company located in    Westminster, Colorado. The Company's proprietary diagnostic    solution is based on a genetic expression system (GES) and    Johne's disease management system, HERDCHECK, designed to    function on a highly automated Fluorogenic PCR platform. This    platform enables GeneThera to offer tests that are presently    not available from other technologies. The GES and HERDCHECK    systems are designed for a host of individual diseases, the    current priority being Johne's disease. For more information,    contact Dr. Tony Milici at 720 439-3011.  <\/p>\n<p>    This press release contains forward-looking statements, which    are made pursuant to the Safe-Harbor provisions of the Private    Securities Litigation Reform Act of 1995. Words such as    \"intends,\" \"believes,\" and similar expressions reflecting    something other than historical fact are intended to identify    forward-looking statements, but are not the exclusive means of    identifying such statements. These forward-looking statements    involve a number of risks and uncertainties, including the    timely development and market acceptance of products and    technologies, the ability to secure additional sources of    finance, the ability to reduce operating expenses, and other    factors described in the Company's filings with the Securities    and Exchange Commission. The actual results that the Company    achieves may differ materially from any forward-looking    statement due to such risks and uncertainties. The Company    undertakes no obligation to revise or update any    forward-looking statements in order to reflect events or    circumstances that may arise after the date of this release.  <\/p>\n<p>    <a href=\"http:\/\/www.genethera.net\" rel=\"nofollow\">http:\/\/www.genethera.net<\/a>  <\/p>\n<\/p>\n<p>Visit link: <\/p>\n<p><a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/applied-genetics-signs-agreement-national-133000885.html;_ylt=A2KJjagT7bRPPB8AXsn_wgt.\" title=\"Applied Genetics Signs Agreement With The National University Of Mexico (UNAM)\">Applied Genetics Signs Agreement With The National University Of Mexico (UNAM)<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> WESTMINSTER, Colo., May 16, 2012 \/PRNewswire\/ -- GeneThera, Inc. (GTHR.PK) announced today that Applied Genetics, GeneThera's majority owned subsidiary, signed a research and test validation agreement with Universidad National Autonoma de Mexico (UNAM) <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/human-genetics\/applied-genetics-signs-agreement-with-the-national-university-of-mexico-unam.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[4],"tags":[],"class_list":["post-44982","post","type-post","status-publish","format-standard","hentry","category-human-genetics"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/44982"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=44982"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/44982\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=44982"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=44982"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=44982"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}